Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and diagnostics.
Pharmaceuticals Division sales were +7% at CER, -4% when reported in CHF and +10% in USD, due to continued high growth in sales of medicines for the treatment of severe diseases; Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases) and Ocrevus (multiple sclerosis) were the top growth drivers.
Diagnostics Division sales were +3% at CER, -7% when reported in CHF and +7% in USD, as demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China.
Login to comment